AGHALEE_PHARMACY_PRACTICE - Accounts

Company registration number NI050422 (Northern Ireland)
AGHALEE PHARMACY PRACTICE LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2023
PAGES FOR FILING WITH REGISTRAR
AGHALEE PHARMACY PRACTICE LTD
CONTENTS
Page
Statement of comprehensive income
Balance sheet
1 - 2
Statement of changes in equity
3
Notes to the financial statements
4 - 12
AGHALEE PHARMACY PRACTICE LTD
BALANCE SHEET
AS AT
30 APRIL 2023
30 April 2023
- 1 -
2023
2022
Notes
£
£
£
£
Fixed assets
Goodwill
5
30,500
61,000
Other intangible assets
5
29,898
31,847
Total intangible assets
60,398
92,847
Tangible assets
6
29,535
36,002
89,933
128,849
Current assets
Stocks
7
30,575
29,500
Debtors
8
159,817
128,196
Cash at bank and in hand
384,918
374,140
575,310
531,836
Creditors: amounts falling due within one year
9
(211,346)
(221,261)
Net current assets
363,964
310,575
Total assets less current liabilities
453,897
439,424
Creditors: amounts falling due after more than one year
10
-
0
(15,161)
Provisions for liabilities
Deferred tax liability
12
1,051
2,251
(1,051)
(2,251)
Net assets
452,846
422,012
Capital and reserves
Called up share capital
13
3
3
Profit and loss reserves
452,843
422,009
Total equity
452,846
422,012
AGHALEE PHARMACY PRACTICE LTD
BALANCE SHEET (CONTINUED)
AS AT
30 APRIL 2023
30 April 2023
- 2 -

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 April 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 26 January 2024
Mrs Zita Graham
Director
Company registration number NI050422 (Northern Ireland)
AGHALEE PHARMACY PRACTICE LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 APRIL 2023
- 3 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 May 2021
3
376,541
376,544
Year ended 30 April 2022:
Profit and total comprehensive income
-
105,468
105,468
Dividends
-
(60,000)
(60,000)
Balance at 30 April 2022
3
422,009
422,012
Year ended 30 April 2023:
Profit and total comprehensive income
-
79,334
79,334
Dividends
-
(48,500)
(48,500)
Balance at 30 April 2023
3
452,843
452,846
AGHALEE PHARMACY PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2023
- 4 -
1
Accounting policies
Company information

Aghalee Pharmacy Practice Ltd is a private company limited by shares incorporated in Northern Ireland. The registered office is 8E Lurgan Road, Aghalee, Craigavon, BT67 0DD.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

AGHALEE PHARMACY PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
1
Accounting policies
(Continued)
- 5 -
1.5
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Investment
No Amortisation
Website
20% Straight Line
1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
25% Straight Line
Fixtures and fittings
25% Straight Line
Computers
25% Straight Line
Motor vehicles
25% Straight Line
Alterations
25% Straight Line
Alterations to office
10% Straight Line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

AGHALEE PHARMACY PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
1
Accounting policies
(Continued)
- 6 -

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.9
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

AGHALEE PHARMACY PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
1
Accounting policies
(Continued)
- 7 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.12
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

AGHALEE PHARMACY PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
1
Accounting policies
(Continued)
- 8 -
1.14
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.15
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
20
20
4
Director's remuneration
2023
2022
£
£
Remuneration for qualifying services
9,900
10,360
AGHALEE PHARMACY PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
- 9 -
5
Intangible fixed assets
Goodwill
Investment
Website
Total
£
£
£
£
Cost
At 1 May 2022 and 30 April 2023
610,000
26,120
9,745
645,865
Amortisation and impairment
At 1 May 2022
549,000
120
3,898
553,018
Amortisation charged for the year
30,500
-
0
1,949
32,449
At 30 April 2023
579,500
120
5,847
585,467
Carrying amount
At 30 April 2023
30,500
26,000
3,898
60,398
At 30 April 2022
61,000
26,000
5,847
92,847
AGHALEE PHARMACY PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
- 10 -
6
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Alterations
Alterations to office
Total
£
£
£
£
£
£
£
Cost
At 1 May 2022
13,967
60,725
3,837
12,780
12,000
60,000
163,309
Additions
-
0
-
0
1,378
-
0
-
0
-
0
1,378
At 30 April 2023
13,967
60,725
5,215
12,780
12,000
60,000
164,687
Depreciation and impairment
At 1 May 2022
12,551
56,608
3,368
12,780
12,000
30,000
127,307
Depreciation charged in the year
354
1,029
462
-
0
-
0
6,000
7,845
At 30 April 2023
12,905
57,637
3,830
12,780
12,000
36,000
135,152
Carrying amount
At 30 April 2023
1,062
3,088
1,385
-
0
-
0
24,000
29,535
At 30 April 2022
1,416
4,117
469
-
0
-
0
30,000
36,002
AGHALEE PHARMACY PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
- 11 -
7
Stocks
2023
2022
£
£
Finished goods and goods for resale
30,575
29,500
8
Debtors
2023
2022
Amounts falling due within one year:
£
£
Trade debtors
124,283
98,789
Other debtors
32,272
29,407
Prepayments and accrued income
3,262
-
0
159,817
128,196
9
Creditors: amounts falling due within one year
2023
2022
Notes
£
£
Bank loans
11
-
0
4,989
Other borrowings
11
33,355
33,355
Trade creditors
133,778
129,630
Corporation tax
28,221
34,343
Other taxation and social security
756
1,212
Other creditors
15,236
17,732
211,346
221,261
10
Creditors: amounts falling due after more than one year
2023
2022
£
£
Other creditors
-
0
15,161
11
Loans and overdrafts
2023
2022
£
£
Bank loans
-
0
4,989
Other loans
33,355
33,355
33,355
38,344
Payable within one year
33,355
38,344
AGHALEE PHARMACY PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2023
- 12 -
12
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:

Liabilities
Liabilities
2023
2022
Balances:
£
£
Accelerated capital allowances
1,051
2,251
2023
Movements in the year:
£
Liability at 1 May 2022
2,251
Credit to profit or loss
(1,200)
Liability at 30 April 2023
1,051
13
Share capital
2023
2022
Ordinary share capital
£
£
Issued and fully paid
Ordinary Shares of £1 each
3
3
14
Related party transactions

The following amounts were outstanding at the reporting end date:

2023
2022
Amounts due from related parties
£
£
Key management personnel
366
266
2023-04-302022-05-01false26 January 2024CCH SoftwareCCH Accounts Production 2023.300No description of principal activityMrs Z GrahamMr Brian GrahamfalseNI0504222022-05-012023-04-30NI0504222023-04-30NI050422core:Goodwill2023-04-30NI050422core:Goodwill2022-04-30NI050422core:OtherResidualIntangibleAssets2023-04-30NI050422core:OtherResidualIntangibleAssets2022-04-30NI0504222022-04-30NI050422core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2023-04-30NI050422core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwill2023-04-30NI050422core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2022-04-30NI050422core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwill2022-04-30NI050422core:PlantMachinery2023-04-30NI050422core:FurnitureFittings2023-04-30NI050422core:ComputerEquipment2023-04-30NI050422core:MotorVehicles2023-04-30NI050422core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2023-04-30NI050422core:Non-standardPPEClass2ComponentTotalPropertyPlantEquipment2023-04-30NI050422core:PlantMachinery2022-04-30NI050422core:FurnitureFittings2022-04-30NI050422core:ComputerEquipment2022-04-30NI050422core:MotorVehicles2022-04-30NI050422core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2022-04-30NI050422core:Non-standardPPEClass2ComponentTotalPropertyPlantEquipment2022-04-30NI050422core:CurrentFinancialInstrumentscore:WithinOneYear2023-04-30NI050422core:CurrentFinancialInstrumentscore:WithinOneYear2022-04-30NI050422core:Non-currentFinancialInstrumentscore:AfterOneYear2023-04-30NI050422core:Non-currentFinancialInstrumentscore:AfterOneYear2022-04-30NI050422core:CurrentFinancialInstruments2023-04-30NI050422core:CurrentFinancialInstruments2022-04-30NI050422core:ShareCapital2023-04-30NI050422core:ShareCapital2022-04-30NI050422core:RetainedEarningsAccumulatedLosses2023-04-30NI050422core:RetainedEarningsAccumulatedLosses2022-04-30NI050422core:ShareCapital2021-04-30NI050422core:RetainedEarningsAccumulatedLosses2021-04-30NI050422bus:Director12022-05-012023-04-30NI050422core:RetainedEarningsAccumulatedLosses2021-05-012022-04-30NI0504222021-05-012022-04-30NI050422core:RetainedEarningsAccumulatedLosses2022-05-012023-04-30NI050422core:Goodwill2022-05-012023-04-30NI050422core:IntangibleAssetsOtherThanGoodwill2022-05-012023-04-30NI050422core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2022-05-012023-04-30NI050422core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwill2022-05-012023-04-30NI050422core:PlantMachinery2022-05-012023-04-30NI050422core:FurnitureFittings2022-05-012023-04-30NI050422core:ComputerEquipment2022-05-012023-04-30NI050422core:MotorVehicles2022-05-012023-04-30NI050422core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2022-05-012023-04-30NI050422core:Non-standardPPEClass2ComponentTotalPropertyPlantEquipment2022-05-012023-04-30NI050422core:Goodwill2022-04-30NI050422core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2022-04-30NI050422core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwill2022-04-30NI0504222022-04-30NI050422core:PlantMachinery2022-04-30NI050422core:FurnitureFittings2022-04-30NI050422core:ComputerEquipment2022-04-30NI050422core:MotorVehicles2022-04-30NI050422core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2022-04-30NI050422core:Non-standardPPEClass2ComponentTotalPropertyPlantEquipment2022-04-30NI050422core:Non-currentFinancialInstruments12023-04-30NI050422core:Non-currentFinancialInstruments12022-04-30NI050422bus:PrivateLimitedCompanyLtd2022-05-012023-04-30NI050422bus:SmallCompaniesRegimeForAccounts2022-05-012023-04-30NI050422bus:FRS1022022-05-012023-04-30NI050422bus:AuditExemptWithAccountantsReport2022-05-012023-04-30NI050422bus:CompanySecretary12022-05-012023-04-30NI050422bus:FullAccounts2022-05-012023-04-30xbrli:purexbrli:sharesiso4217:GBP